- Home
- BIIB vs PKG Comparison
BIIB vs PKG Comparison
Compare BIIB & PKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PKG
- Stock Information
- Founded
- BIIB 1978
- PKG 1867
- Country
- BIIB United States
- PKG United States
- Employees
- BIIB 7605
- PKG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PKG Containers/Packaging
- Sector
- BIIB Health Care
- PKG Consumer Discretionary
- Exchange
- BIIB Nasdaq
- PKG Nasdaq
- Market Cap
- BIIB 20.6B
- PKG 20.4B
- IPO Year
- BIIB 1991
- PKG 2000
- Fundamental
- Price
- BIIB $140.60
- PKG $207.88
- Analyst Decision
- BIIB Buy
- PKG Strong Buy
- Analyst Count
- BIIB 27
- PKG 6
- Target Price
- BIIB $220.50
- PKG $244.33
- AVG Volume (30 Days)
- BIIB 1.5M
- PKG 917.0K
- Earning Date
- BIIB 02-12-2025
- PKG 01-28-2025
- Dividend Yield
- BIIB N/A
- PKG 2.41%
- EPS Growth
- BIIB 40.28
- PKG 5.31
- EPS
- BIIB 11.18
- PKG 8.93
- Revenue
- BIIB $9,675,900,000.00
- PKG $8,383,299,999.00
- Revenue This Year
- BIIB N/A
- PKG $7.74
- Revenue Next Year
- BIIB $1.57
- PKG $3.80
- P/E Ratio
- BIIB $12.65
- PKG $23.27
- Revenue Growth
- BIIB N/A
- PKG 7.45
- 52 Week Low
- BIIB $128.51
- PKG $169.00
- 52 Week High
- BIIB $238.00
- PKG $250.82
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- PKG 33.14
- Support Level
- BIIB $135.02
- PKG $201.69
- Resistance Level
- BIIB $141.69
- PKG $213.45
- Average True Range (ATR)
- BIIB 4.00
- PKG 3.82
- MACD
- BIIB 0.04
- PKG 0.19
- Stochastic Oscillator
- BIIB 59.44
- PKG 49.88
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 4.5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.